Cyclophilin-A (CypA) is a cyclosporine-binding protein, which may play a role in cyclosporin A-mediated immunosuppression.
Cyclophilins are peptidylprolyl isomerases (PPIases) that catalyze the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerate the processing of proteins.
CypA can also interact with several HIV proteins, including p55 gag, Vpr, and capsid protein, and has been shown to be necessary for the formation of infectious HIV virions.
With access to a team of expert staff and specialist equipment, the University of Edinburgh is able to provide recombinant human CypA for laboratory research use.
Additional batch-specific protein activity can be verified by PPIase assay and / or by SPR assay.
Please see the Product Datasheet for further information and specifications.
Prices for Cyclophilin-A products and additional analytical verification services are as follows:
|
Cyclophilin-A, 1 mg quantity
|
£1,130.00
|
|
Cyclophilin-A, 1 mg quantity with batch specific activity verification by PPIase
|
£2,373.00
|
|
Cyclophilin-A, 1 mg quantity with batch specific activity verification by SPR
|
£2,373.00
|
|
Cyclophilin-A, 2 mg quantity
|
£1,413.00
|
|
Cyclophilin-A, 2 mg quantity with batch specific activity verification by PPIase
|
£2,656.00
|
|
Cyclophilin-A, 2 mg quantity with batch specific activity verification by SPR
|
£2,656.00
|
Materials are provided for LABORATORY RESEARCH USE ONLY.
Please note that an approved licence is required before commercial files related to this product can be downloaded. Such files are indicated by .
| Files |
|
File description:ID2689_Cyclophilin-A_Supply_Agreement_v3_December2018
File name:ID2689_Cyclophilin-A_Supply_Agreement_v3_December2018.pdf
|
| File size:445.99 KB |
File version:3.00
|
|
|
|
File description:Datasheet for Recombinant Human Cyclophilin-A
File name:ID2689_Cyclophilin-A_Datasheet.pdf
|
| File size:16.15 KB |
File version:1.0
|
|
|
There are no references for this product.
There are no support topics defined for this product.
